Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) EPS (Weighted Average and Diluted) (2020 - 2026)

Opus Genetics has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.75 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 212.5% to -$0.75 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.33 through Mar 2026, up 36.67% year-over-year, with the annual reading at -$0.8 for FY2025, 62.79% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.75 for Q1 2026 at Opus Genetics, down from -$0.21 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.69 in Q4 2022 and troughed at -$1.27 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.25 (2022), against an average of -$0.2.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 1038.89% in 2022 and then plummeted 504.76% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.69 in 2022, then tumbled by 112.43% to -$0.21 in 2023, then plummeted by 504.76% to -$1.27 in 2024, then skyrocketed by 83.46% to -$0.21 in 2025, then crashed by 257.14% to -$0.75 in 2026.
  • Per Business Quant, the three most recent readings for IRD's EPS (Weighted Average and Diluted) are -$0.75 (Q1 2026), -$0.21 (Q4 2025), and -$0.25 (Q3 2025).